Estrogen replacement therapy is commonly used to replace the loss of estrogen in post-menopausal women. However, it is not suitable to be used in women taking tamoxifen as both of the drugs increase the risk of endometrial cancer. This project aimed to study the potential of using the natural compound glabridin in combination with tamoxifen as a drug for estrogen replacement therapy. Ishikawa and MCF-7 cells were used to investigate the estrogenic activities stimulated by the combination of tamoxifen and glabridin through ALP and MTT assays. The expressions of the ESR1 and bcl-2 genes have also been determined using RT-PCR. The results indicated that the combination of 1×10 -5 M tamoxifen and 1×10 -6 M glabridin exhibited estrogenic activities and suppressed cell growth in both cell lines. The relative expressions of ESR1 and bcl-2 genes indicated that the estrogenicity expressed by the combinatory drug was regulated by estrogen receptor α; however, the reduction in cell proliferation was not modulated by bcl-2 anti-apoptotic proteins. These results suggested that the combination of tamoxifen and glabridin has potential to be used as an estrogen replacement drug with a reduced risk of endometrial cancer that has arisen from the intake of tamoxifen.
Estrogens are steroid hormones that regulate the growth and differentiation of estrogen-sensitive cells, as well as the reproductive system and the menstrual cycle in women. The binding of estrogen to estrogen receptors (ERs) regulates gene expressions by activating or de-activating estrogen-responsive genes, followed by an increase or decrease of the corresponding proteins resulting in a physiological response [1] . Menopause is a condition where the ovaries fail to produce sufficient estrogen. To overcome postmenopausal symptoms, estrogen replacement therapy became the most sought after treatment for post-menopausal women since 1951. Studies have shown that short term usage of estrogen replacement therapy is very effective in treating vasomotor and urogenital symptoms. However, long term estrogen replacement therapy increases the risk of endometrial and breast cancer in women [2, 3] . Women with breast cancer experience more severe post-menopausal symptoms during their menopausal transition, especially after they have received chemotherapy [4] . Tamoxifen is commonly used to treat breast cancer; however, it does not provide sufficient estrogenic activities to relieve post-menopausal symptoms and yet, increases the risk of endometrial cancer [5] . Sestak et al. [6] also indicated that estrogen replacement therapy has limited effectiveness in treating post-menopausal symptoms in women taking tamoxifen and the combination of these two does not reduce the risk of endometrial cancer [7] . Glabridin is an isoflavan extracted from licorice (genus Glycyrrhiza) roots [8] , which is also known as a phytoestrogen due to the similarity of its structure and lipophilicity to 17β-estradiol. Studies indicated that glabridin is able to bind to the ERs and induce estrogenic responses in cardiovascular and bone tissues, suggesting its possibility to be used in estrogen replacement therapy [9] .
This study investigated the estrogenic activities, the degree of cell proliferation and the regulation of ESR1 and bcl-2 genes stimulated by the combination of tamoxifen and glabridin in Ishikawa (endometrial adenocarcinoma) and MCF-7 (breast adenocarcinoma) cell lines. The ESR1 gene codes for estrogen receptor alpha (ERα), which is an estrogen mediated transcription factor found in estrogen-sensitive tissues, such as breast and endometrial tissues [10] . Since ERα is highly associated with estrogenic activities and is used in the diagnosis and prognosis for estrogen-mediated tumor growth, estrogen signaling pathway through ERα is a common target for the treatment of breast and endometrial cancer [11] .
The B-cell lymphoma 2 (bcl-2) protein, encoded by the bcl-2 gene, is an anti-apoptotic protein where the overexpression alters the normal cell cycle, resulting in an uncontrolled cell division that leads to tumor formation [12] . Bcl-2 is found to be expressed in 40-80% of the breast cancer cases and the treatments for these patients mostly focus on anti-estrogen therapies, such as tamoxifen, which is then associated with a decreased level of bcl-2 expression [13] . Jo et al. [14] also suggested that licorice roots modulate the expression of bcl-2 gene and could potentially be used as a chemopreventive agent against breast cancer.
The concentration of the combinatory drug was selected based on its ability to exhibit estrogenic activity with minimal stimulatory effect in endometrial cells, at the same time, maintaining the therapeutic effect of tamoxifen in breast cancer cells. The combination of 1×10 -5 M tamoxifen and 1×10 -6 M glabridin was chosen according to these criteria and the results of ALP and MTT assays are presented in ALP activities expressed by Ishikawa cells treated with glabridin, tamoxifen and the combination of both were used as an indicator for the estrogenic activity of the treated cells to investigate the ability of the test compounds to act as a drug for estrogen replacement therapy [15] . Cell proliferation of the treated Ishikawa and MCF-7 cells measured by MTT assay was used to investigate the estrogenstimulated cell proliferation which acts as an important factor in estrogen replacement drug to avoid the increased risk of endometrial and breast cancers [16] . Results showed that the combinatory treatment exhibited an estrogenic activity that is two-fold lower compared with the individual treatments. However, it showed a decrease in the proliferation of Ishikawa cells compared with the individual treatments, suggesting a reduced risk of endometrial cancer in the combinatory treatment. It also showed a reduction in the cell proliferation of MCF-7 cells by two-fold compared with the treatment of tamoxifen alone, signifying an enhancement in the therapeutic effect of the combinatory drug in treating breast cancer.
The increasing ALP activity in Ishikawa cells treated with tamoxifen and glabridin suggested that these compounds expressed estrogenic activity through the mediation of ER, whereby the activation of ER is able to produce an estrogen-dependent alkaline phosphatase protein. Therefore, the stimulatory effects on the cell growth in Ishikawa cells suggested that tamoxifen and glabridin act as agonists in endometrial cells, which conforms to the findings of previous studies made by Tamir et al. [17] and Johnson et al. [18] . In MCF-7 cells, tamoxifen at 1×10 -5 M has been shown to inhibit cell proliferation by repressing the estrogen responsive gene [19] . Previous study indicated that glabridin inhibits the proliferation of estrogen-dependent cancer cells due to its low estrogenic potential compared with estrogen [20] . However, in this study, glabridin was able to stimulate cell proliferation in MCF-7 cells under an estrogen-free condition. This observation supports a past report made by Rice and Whitehead [21] in which they suggested that the incidence of breast cancer in Western countries is three times that of the Eastern countries, due to the high dietary intake of phytoestrogens in Western countries. Figure 4 shows the fold changes of the gene expression of ESR1 and bcl-2 genes in Ishikawa and MCF-7 cells. In Ishikawa cells, the interaction of tamoxifen and glabridin with the ERs increased the production of the estrogen-mediated ALP and stimulated cell proliferation of Ishikawa cells. However, the ESR1 gene was not up-regulated by glabridin and tamoxifen in Ishikawa cells, suggesting that ERα was not over-expressed in these proliferating cells [18] . They also had no effect on the expression of bcl-2 gene, proposing that other anti-apoptotic proteins may have been involved in stimulating the cell proliferation of Ishikawa cells [22] . However, the combinatory drug was found to up-regulate ESR1 and bcl-2 genes by 2-fold without stimulating cell proliferation in Ishikawa cells in comparison with the untreated cells. This observation Combination of tamoxifen and glabridin for estrogen replacement therapy Natural Product Communications Vol. 10 (9) 2015 1575 suggested that the combination of tamoxifen and glabridin has a different molecular mechanism compared with the individual drugs, whereas the growth inhibitory effect of the combinatory drug on Ishikawa cells is mediated neither through the ERα nor the apoptosis pathway.
In MCF-7 cells, 1×10 -6 M glabridin exhibited estrogenic activity through the up-regulation of ESR1 and bcl-2 genes by 9 and 13-fold respectively, leading to the inhibition of apoptosis and the stimulation of cell proliferation [23] . On the other hand, 1×10 -5 M tamoxifen reduced the cell proliferation in MCF-7 cells. However, ESR1 and bcl-2 genes were found to be up-regulated by 3 and 4 fold respectively in this cell line. Since tamoxifen exhibits antiestrogenic activities in breast cancer cells, this study indicated that tamoxifen up-regulated the expression of ERα and exerted its antagonistic effect through ERα in MCF-7 cells [24] . Although bcl-2 is an anti-apoptotic protein that inhibits apoptosis, it has also been reported to be involved in the surveillance of oncogenesis and the suppression of tumorigenesis [25] . Therefore, the up-regulation of bcl-2 gene may explain the effect of tamoxifen in decreasing cell proliferation in MCF-7 cells. The fold changes of the ESR1 and bcl-2 gene expressions in MCF-7 cells treated with the combinatory drug were similar to those induced by tamoxifen alone. However, the growth inhibitory effect of the combinatory drug was two-fold higher compared with tamoxifen alone, proposing the synergistic effect of glabridin to decrease cell proliferation in breast cancer cells [26] .
The combinatory drugs (tamoxifen and glabridin) have potential to be used as an estrogen replacement drug in post-menopausal women with breast cancer, but only to a certain extent, as the estrogenic activities provided were lower than the natural hormone in the body, 17β-estradiol. Since endometrial cancer is highly correlated with the usage of tamoxifen, the combinatory drug provides benefits for women with breast cancer that are currently using tamoxifen as a chemotherapy drug to reduce the risk of endometrial cancer.
Experimental
Cell culture and drug testing: Ishikawa and MCF-7 cells were cultured in minimum essential medium and RPMI medium respectively, supplemented with 10% fetal bovine serum, 1% 2nM glutamine and 1% anti-fungal anti-bacterial agent. The cells were cultured to 70-80% confluence and the medium was changed to estrogen free basal medium for 24 h before being seeded in 96-wellplates with a seeding density of 1.5x10 4 cells/well. The cells were then incubated in a 37°C CO 2 incubator for 24 h to allow cell adherence. Glabridin and tamoxifen in concentrations ranging from 1×10 -5 M to 1×10 -10 M were added to each well to a total volume of 150 μL per well, either alone or in combination. The test compounds were dissolved in ethanol and diluted to the required concentration of the compound with a final concentration of 0.1% ethanol. All test compounds were duplicated and were incubated for 72 h [15] .
ALP assay:
Test compounds in the 96-well-plates were removed and the wells were washed twice with ice cold PBS (10 mM sodium phosphate, 0.15 M NaCl, pH 7.4). The plates were placed in a -80°C freezer for 30 min and thawed in a 37°C water bath for 5 min. A volume of 50 μL of 5 mM ice cold p-nitrophenyl phosphate (pNPP) was added to each well and the absorbance values of the yellow solutions developed were monitored periodically by using a fluorimeter until the maximum value of the estrogen-treated cells reach an absorbance value of 1.2 [15] .
MTT assay: MTT solution was prepared by dissolving 5.0 mg of MTT powder in 1 mL PBS solution. Ten μL of MTT solution was added to the wells and incubated for 3.5 -4 h. The solutions in the wells were removed and the dark purple crystals (formazan) formed were dissolved in 100 μL DMSO. The plates were read at 595 nm by using a microplate reader and the absorbance values were recorded [16] .
Quantitative real-time PCR:
Relative quantification was used to compare the gene expressions of ESR1 and bcl-2 genes between non-treated and treated cells, normalized by GAPDH gene [27] The primer sequences and the product sizes of GAPDH, ESR1 and bcl-2 genes are shown in Table 1 . qPCRBIO SyGreen Mix Lo-ROX manufactured by PCRBIOSYSTEMS was used in the RT-PCR following the protocol provided. The relative expressions of the genes between treated and non-treated cells were determined from the Ct (threshold cycle) values. The fold changes were determined using the equation of 2 (-ΔΔCt) , followed by calculations of the standard deviations [28] . Statistical analysis: All graph construction and statistical analyses were made using IBM ® SPSS ® Version 20. p-Value was calculated using the Student T-test to compare the ALP activities and the percentages of cell proliferation obtained between the sample and the negative control. The standard deviations of the fold changes obtained from the Ct values were calculated manually using the methods provided by Livak and Schmittgen [28] .
